Toll-like receptor 9 in murine lupus: More friend than foe!

Immunobiology

Volumn 213, Issue 2, 2008, Pages 151-157

  Yu, Philipp ^a   Musette, Philippe ^b   Peng, Stanford L ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Inflammation   (United States)

Author keywords

Lupus; Murine models; SLE; TLR9

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; DNA; PHOSPHOLIPASE C GAMMA2; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DISEASE EXACERBATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PATHOGENESIS; PATTERN RECOGNITION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 38649129409     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2007.08.002     Document Type: Article

References (56)

1. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., and Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100 (2003) 2610-2615
2. Banchereau J., and Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
3. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., and Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199 (2004) 1631-1640
4. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., and Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202 (2005) 321-331
5. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
6. Danchenko N., Satia J.A., and Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15 (2006) 308-318
7. Dasari P., Nicholson I.C., Hodge G., Dandie G.W., and Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 236 (2005) 140-145
8. Deane J.A., and Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J. Immunol. 177 (2006) 6573-6578
9. Del-Rey M., Ruiz-Contreras J., Bosque A., Calleja S., Gomez-Rial J., Roldan E., Morales P., Serrano A., Anel A., Paz-Artal E., and Allende L.M. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood 108 (2006) 1306-1312
10. Ehlers M., and Ravetch J.V. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol. 28 (2007) 74-79
11. Ehlers M., Fukuyama H., McGaha T.L., Aderem A., and Ravetch J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203 (2006) 553-561
12. Fairhurst A.M., Wandstrat A.E., and Wakeland E.K. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv. Immunol. 92 (2006) 1-69
13. Flierman R., and Daha M.R. The clearance of apoptotic cells by complement. Immunobiology 212 (2007) 363-370
14. Fukuyama H., Nimmerjahn F., and Ravetch J.V. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6 (2005) 99-106
15. Hamilton K.J., Schett G., Reich 3rd C.F., Smolen J.S., and Pisetsky D.S. The binding of sera of patients with SLE to bacterial and mammalian DNA. Clin. Immunol. 118 (2006) 209-218
16. Hibbs M.L., Harder K.W., Armes J., Kountouri N., Quilici C., Casagranda F., Dunn A.R., and Tarlinton D.M. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J. Exp. Med. 196 (2002) 1593-1604
17. Hoshino K., Sugiyama T., Matsumoto M., Tanaka T., Saito M., Hemmi H., Ohara O., Akira S., and Kaisho T. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 440 (2006) 949-953
18. Hron J.D., and Peng S.L. Type I IFN protects against murine lupus. J. Immunol. 173 (2004) 2134-2142
19. Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J., Jackson C.E., Wang J., Fleisher T., Straus S.E., and Puck J.M. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J. Pediatr. 133 (1998) 629-633
20. Ishii K.J., and Akira S. Innate immune recognition of, and regulation by, DNA. Trends Immunol. 27 (2006) 525-532
21. Kono D.H., and Theofilopoulos A.N. Genetics of SLE in mice. Springer Semin. Immunopathol. 28 (2006) 83-96
22. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
23. Lanzavecchia A., and Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr. Opin. Immunol. 19 (2007) 268-274
24. Lartigue A., Courville P., Auquit I., Francois A., Arnoult C., Tron F., Gilbert D., and Musette P. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177 (2006) 1349-1354
25. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., Christensen S.R., Shlomchik M.J., Viglianti G.A., Rifkin I.R., and Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202 (2005) 1171-1177
26. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002) 603-607
27. Lenert P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?. Clin. Exp. Immunol. 140 (2005) 1-10
28. Liu K., and Mohan C. What do mouse models teach us about human SLE?. Clin. Immunol. 119 (2006) 123-130
29. Mahoney J.A., and Rosen A. Apoptosis and autoimmunity. Curr. Opin. Immunol. 17 (2005) 583-588
30. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006) 823-835
31. Martin F., and Kearney J.F. Marginal-zone B cells. Nat. Rev. Immunol. 2 (2002) 323-335
32. Meyers J.A., Mangini A.J., Nagai T., Roff C.F., Sehy D., van Seventer G.A., and van Seventer J.M. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 35 (2006) 235-246
33. Okabe Y., Kawane K., Akira S., Taniguchi T., and Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J. Exp. Med. 202 (2005) 1333-1339
34. Patole P.S., Zecher D., Pawar R.D., Grone H.J., Schlondorff D., and Anders H.J. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16 (2005) 3273-3280
35. Pawar R.D., Patole P.S., Ellwart A., Lech M., Segerer S., Schlondorff D., and Anders H.J. Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J. Am. Soc. Nephrol. 17 (2006) 3365-3373
36. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., and Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 (2006) 1669-1672
37. Rieux-Laucat F., Le Deist F., and Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 10 (2003) 124-133
38. Rivero S.J., Diaz-Jouanen E., and Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum. 21 (1978) 295-305
39. Ronnblom L.E., Alm G.V., and Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 30 (1991) 537-540
40. Rothenburg S., Schwartz T., Koch-Nolte F., and Haag F. Complex regulation of the human gene for the Z-DNA binding protein DLM-1. Nucl. Acids Res. 30 (2002) 993-1000
41. Rouquette A.M., and Desgruelles C. Detection of antibodies to dsDNA: an overview of laboratory assays. Lupus 15 (2006) 403-407
42. Schwarting A., Paul K., Tschirner S., Menke J., Hansen T., Brenner W., Kelley V.R., Relle M., and Galle P.R. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16 (2005) 3264-3272
43. Stetson D.B., and Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24 (2006) 93-103
44. Tabeta K., Hoebe K., Janssen E.M., Du X., Georgel P., Crozat K., Mudd S., Mann N., Sovath S., Goode J., Shamel L., Herskovits A.A., Portnoy D.A., Cooke M., Tarantino L.M., Wiltshire T., Steinberg B.E., Grinstein S., and Beutler B. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7 (2006) 156-164
45. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., and Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
46. Tao K., Fujii M., Tsukumo S.I., Maekawa Y., Kishihara K., Kimoto Y., Horiuchi T., Hisaeda H., Akira S., Kagami S., and Yasutomo K. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann. Rheum. Dis. 66 (2007) 905-909
47. Tran T.T., Reich 3rd C.F., Alam M., and Pisetsky D.S. Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. Clin. Immunol. 109 (2003) 278-287
48. Wellmann U., Werner A., and Winkler T.H. Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA. Eur. J. Immunol. 31 (2001) 2800-2810
49. Wellmann U., Letz M., Herrmann M., Angermuller S., Kalden J.R., and Winkler T.H. The evolution of human anti-double-stranded DNA autoantibodies. Proc. Natl. Acad. Sci. USA 102 (2005) 9258-9263
50. Wu X., and Peng S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54 (2006) 336-342
51. Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Marodi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A., Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., and Casanova J.L. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23 (2005) 465-478
52. Yasuda K., Yu P., Kirschning C.J., Schlatter B., Schmitz F., Heit A., Bauer S., Hochrein H., and Wagner H. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 174 (2005) 6129-6136
53. Yu C.C., Mamchak A.A., and DeFranco A.L. Signaling mutations and autoimmunity. Curr. Dir. Autoimmun. 6 (2003) 61-88
54. Yu P., Constien R., Dear N., Katan M., Hanke P., Bunney T.D., Kunder S., Quintanilla-Martinez L., Huffstadt U., Schroder A., Jones N.P., Peters T., Fuchs H., de Angelis M.H., Nehls M., Grosse J., Wabnitz P., Meyer T.P., Yasuda K., Schiemann M., Schneider-Fresenius C., Jagla W., Russ A., Popp A., Josephs M., Marquardt A., Laufs J., Schmittwolf C., Wagner H., Pfeffer K., and Mudde G.C. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity 22 (2005) 451-465
55. Yu P., Wellmann U., Kunder S., Quintanilla-Martinez L., Jennen L., Dear N., Amann K., Bauer S., Winkler T.H., and Wagner H. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18 (2006) 1211-1219
56. Yurasov S., Hammersen J., Tiller T., Tsuiji M., and Wardemann H. B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus. Ann. NY Acad. Sci. 1062 (2005) 165-174